Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also develops Pitolisant that is in Phase 3 clinical trial for the treatment of Prader-Willi Syndrome (PWS); in Phase 2 clinical trial to treat Myotonic Dystrophy (DM1); and is in Phase 2 clinical trials for the treatment of Pitolisant Gastro-Resistant (GR) and Pitolisant High-Dose (HD). In addition, the company's products under development include BP1.15205, an orexin 2 receptor agonist for the treatment of narcolepsy and other potential indications; and HBS-102, a melanin-concentrating hormone receptor type 1 (MCHR1) antagonist. Further, it develops ZYN-002 that is in a Phase 3 registrational trial for the treatment of Fragile X Syndrome; and 22q Deletion Syndrome, a disorder caused by a small missing piece on the long arm of the 22nd chromosome. Additionally, the company is developing EPX-100 (clemizole hydrochloride), a serotonin (5HT-2) receptor agonist to treat dravet syndrome and lenox-gastaut syndrome; EPX-200 (liquid formulation of lorcaserin), a selective 5HT-2C agonist to treat developmental and epileptic encephalopathies; CBS105 for the treatment-resistant narcolepsy; and CBS104 for refractory epilepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.…
Harmony Biosciences to Participate in Upcoming Investor Conferences
Harmony Biosciences Holdings (NASDAQ: HRMY) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 293 employees.
The shares were at 32.59 USD on 20 November 2026, up 3.7% over 52 weeks. Its 52-week range is 25.90 USD to 43.49 USD: the price is 25.1% below the high and 25.8% above the low.
At a market capitalisation of 1.91B USD, it trades at 10.8 times trailing earnings and 5.4 times forward earnings. The median trailing P/E of its 13 largest Biotechnology peers is 33.1, a discount of 67% for HRMY.
Harmony Biosciences Holdings reports return on equity of 18.2%, an operating margin of 22.2% and revenue up 12.3% year over year.
It holds more cash than debt, a net cash position of 616.22M USD. Its Piotroski F-score is 5 out of 9, an average reading of its financial health. 12 analysts cover the stock, with an average rating of Buy; their mean price target of 48.08 USD is 47.5% above the current price. The next earnings report is expected on 23 February 2027.